Michael Ryan is a Cardiology physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
700 NE 87th Ave
Vancouver, WA 98664
Telephone
608-822-7783Registry record last updated 26 Jun 2018.
Clinical trials
- TSO for Plaque Psoriasis
Sponsor: Coronado Biosciences, Inc.
- Footwear and Injury Prevention Study
Sponsor: University of British Columbia
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABIOMEDProgram year20251 payment
- ABIOMEDProgram year20231 payment
- Boston Scientific CorporationProgram year20222 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
82.7%Statin19%Atorvastatin Calcium62%Rosuvastatin Calcium25%Pravastatin Sodium8%Simvastatin4%Part D<11 patientsBeta blocker15.5%Metoprolol Succinate58%Metoprolol Tartrate23%Carvedilol15%Atenolol3%Part D<11 patients+ 15 more classes in this area
Blood & clotting
12.9%Factor Xa inhibitor8%Eliquis100%Part D≥102 patientsP2Y12 inhibitor3.2%Clopidogrel89%Brilinta11%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
4.4%SGLT2 inhibitor2.3%Jardiance83%Farxiga17%Part D<11 patientsPotassium supplement1.7%Potassium Chloride100%Part D≥27 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”